Skip to main content
letter
. 2020 Jun 17;135:98–100. doi: 10.1016/j.ejca.2020.04.039

Table 1b.

Patients given treatment with a palliative intent.

Tumour type Total number of patients /1st line Standard oncological treatment or standard surveillance or investigation pts/1st line COVID treatment option with no loss of chance pts/1st line Delay or pause in treatment or surveillance without major impact pts/1st line Treatment or abstention with possible impact on tumour growth or symptoms but limited impact on duration of survival pts/1st line Palliative care approach without impact of COVID pts/1st line
Urological cancer 39/25 21/15 5/3 6/4 2/2 5/1
Non prostate GU tumour 30 17/13 2/0 5/4 2/2 4/1
Prostate cancer 9 4/2 3/3 1/0 1/0
Brain primary tumours 17/4 3/2 3/0 4/0 7/2
Glioblastoma/high grade glioma 14 3/2 1/0 4/0 6/2
Non glioblastoma/high grade gliomas 3 2/0 1/0
Head and neck carcinoma 12/7 6/2 5/4 1/1
Lung cancer 5/3 2/1 1/0 2/2
Breast cancer 6/3 2/1 2/1 2/1
Gynaecological cancer 4/2 1/0 2/2 1/0
Gastrointestinal cancer 2/1 2/1
Cancer of unknown primary site 3/3 2/2 1/1
TOTAL 88/48 38/24 13/8 14/8 8/2 15/6

COVID, coronavirus disease.

HHS Vulnerability Disclosure